WHO Declares JN.1 a COVID Variant of Interest as It Spreads Widely
Medically reviewed by Drugs.com.
By Robin Foster HealthDay Reporter
WEDNESDAY, Dec. 20, 2023 -- The new COVID variant known as JN.1 was named a "variant of interest" by the World Health Organization on Tuesday, which means health officials are now closely tracking its rapid spread across the globe.
So far, the highly mutated variant has not been shown to trigger more severe illness than previous incarnations of the coronavirus. Still, it is spreading faster than its ancestor, the BA.2.86 variant.
"JN.1 continues to be reported in multiple countries, and its prevalence has been rapidly increasing globally and now represents the vast majority of BA.2.86 descendent lineages reported," the WHO wrote in its latest report.
The WHO defines variants of interest as those that are concerning enough to trigger stepped up laboratory studies and field investigations of their spread.
Variants of interest must also have genetic mutations that change a key characteristic of the virus, like its transmissibility or how well it evades treatments and vaccines. The strain must also be growing in a way that it could be "an emerging risk to global public health."
The U.S. Centers for Disease Control and Prevention uses a similar system to classify variants based on their risk to Americans, but the agency has not yet classified JN.1 as a "variant of interest."
However, the WHO said early evidence shows JN.1's mutations do appear to boost its ability to slip past the body's immune defenses.
"Based on its genetic features, JN.1 may possess some antigenic advantage evading previous immunity," the WHO said in its report.
Estimates published by the CDC earlier this month showed JN.1 was the fastest-growing strain in the United States, accounting for more than 1 in 5 cases nationwide. The variant is on track to become dominant nationwide, the CDC has said.
New variant estimates are expected to be published by the CDC on Friday.
Even as JN.1 spreads widely, this season's updated COVID-19 vaccines are still expected to guard against infection from the JN.1variant, the WHO added.
But the WHO has acknowledged early studies of the variant have discovered lower "cross neutralization" in tests designed to mimic the shots' protection.
"[D]espite the reduction in JN.1 neutralization, protection by XBB.1.5 monovalent vaccines are likely to be effective against JN.1," the WHO noted in its report.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2023-12-20 22:15
Read more
- Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety
- More Kids With Food Allergies Are Needing Psychological Care
- Novel Imaging Technique Accurate for Detecting Clear-Cell Renal Cell Cancer
- ACAAI: Many Anaphylaxis Protocols Are Incomplete, Outdated
- Skin Patch Uses 'Imperceptible' Electric Zaps to Heal Wounds Without Drugs
- Overtreatment Common for Older Men With Prostate Cancer
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions